S. Bhattacharyya

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective

Anand A. Dalal, D. Brixner, J. Biskupiak, 2018, Journal of managed care & specialty pharmacy.

Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data

G. Joseph, Lei Chen, A. Guérin, 2017, Journal of medical economics.

Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

Jipan Xie, G. Joseph, E. Stein, 2018, PharmacoEconomics.

Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States

G. Joseph, E. Stein, Wei Gao, 2018, Health and Quality of Life Outcomes.

Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2− advanced or metastatic breast cancer

Anand A. Dalal, D. Brixner, R. Hettle, 2018, Current medical research and opinion.